Lyra Therapeutics Inc (NASDAQ:LYRA) traded at $0.18 at close of the session on Monday, March 10 and made a downward move of -4.99% on its previous day’s price.
Lyra Therapeutics Inc has a market cap of $11.96 million and is expected to release its quarterly earnings report in April.
The median projection represents growth squeezing down to 41.10% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 1.52M, or -2.21% down from figures reported last year.
On the other hand, looking at the outlook for the LYRA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Lyra Therapeutics Inc (LYRA) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -8.11% off its SMA20 and -6.43% from its 50-day simple moving average. The RSI (14) is pointing at 42.12 while the volatility over the past week is 7.10% and jumps to 7.73% over the past one month. The beta value is -0.15, while the average true range (ATR) is currently pointing at 0.02. The average price target for the stock over the next 12 months is $0.5, with the estimates having a low of $0.5 and a high of $0.5. These price ends are -177.78% and -177.78% off the current price level respectively, although investors could be excited at the prospect of a -177.78% if the LYRA share price touches on the median price of $0.5.
